J2265 HCPCS code: Injection, minocycline hydrochloride, 1 mg
J2265 is the HCPCS Level II code for injection, minocycline hydrochloride, 1 mg. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 400 per day on outpatient hospital claims.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2012-01-01 |
| Last action effective | 2017-01-01 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 400 | Prescribing Information |
| practitioner claims | 400 | Prescribing Information |
What changed for J2265
- 2012-01-01: J2265 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J2265?
J2265 is the HCPCS Level II code for injection, minocycline hydrochloride, 1 mg. Short descriptor: "Minocycline hydrochloride".
Does Medicare cover J2265?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J2265 can be billed per day?
400 on outpatient hospital claims; 400 on practitioner claims (NCCI medically unlikely edits).
Related J22 codes
- J2210 — Injection, methylergonovine maleate, up to 0.2 mg
- J2212 — Injection, methylnaltrexone, 0.1 mg
- J2246 — Injection, micafungin in sodium (baxter), not therapeutically equivalent to j2248, 1 mg
- J2247 — Injection, micafungin sodium (par pharm) not thereapeutically equivalent to j2248, 1 mg
- J2248 — Injection, micafungin sodium, 1 mg
- J2249 — Injection, remimazolam, 1 mg
- J2250 — Injection, midazolam hydrochloride, per 1 mg
- J2251 — Injection, midazolam in 0.9% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2252 — Injection, midazolam in 0.8% sodium chloride, intravenous, not therapeutically equivalent to j2250, 1 mg
- J2253 — Injection, midazolam (seizalam), 1 mg
- J2260 — Injection, milrinone lactate, 5 mg
- J2267 — Injection, mirikizumab-mrkz, 1 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J2265
- Watch J2265 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J2265
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.